Jonathan L Prenner1, Lawrence S Halperin2, Catherine Rycroft3, Susan Hogue4, Zinaria Williams Liu5, Robert Seibert5. 1. NJ Retina, Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. Electronic address: jonathanprenner@gmail.com. 2. Retina Group of Florida, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, Florida. 3. RTI Health Solutions, Manchester, United Kingdom. 4. RTI Health Solutions, Research Triangle Park, North Carolina. 5. Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
Abstract
PURPOSE: To examine the time burden of managing neovascular age-related macular degeneration (AMD) imposed on physicians, staff, patients, and caregivers. DESIGN: Mixed-methods, prospective, observational time-and-motion study. METHODS: The multicenter study was conducted from March 2011 through August 2012. Retina specialists administering ≥50 vascular endothelial growth factor (VEGF)-inhibitor injections monthly were surveyed and completed records for ≥5 patients scheduled for office visits within 3 weeks for anti-VEGF injection or monitoring. A survey was administered to 75 neovascular AMD patients aged ≥50 years who received ≥1 anti-VEGF injection in the past 6 months. Telephone interviews were conducted with 13 neovascular AMD patient caregivers. RESULTS: Fifty-six physicians provided data for 221 patients with neovascular AMD. Patients accounted for 20% of the health care staff's time per week, with an average of 23 staff members. An average patient visit for neovascular AMD was 90 minutes (range: 13 minutes to >4 hours). Patients reported an average time per visit of almost 12 hours, including preappointment preparation (16 minutes), travel (66 minutes), waiting time (37 minutes), treatment time (43 minutes), and postappointment recovery (9 hours). Patients stated that caregivers took time away from work (22%) and personal activities (28%) to provide transportation to appointments. CONCLUSIONS: Neovascular AMD management imposes a substantial time burden on physicians, staff, patients, and caregivers. There may be a need for additional support and/or reimbursement for services required by patients and caregivers and provided by physicians.
PURPOSE: To examine the time burden of managing neovascular age-related macular degeneration (AMD) imposed on physicians, staff, patients, and caregivers. DESIGN: Mixed-methods, prospective, observational time-and-motion study. METHODS: The multicenter study was conducted from March 2011 through August 2012. Retina specialists administering ≥50 vascular endothelial growth factor (VEGF)-inhibitor injections monthly were surveyed and completed records for ≥5 patients scheduled for office visits within 3 weeks for anti-VEGF injection or monitoring. A survey was administered to 75 neovascular AMDpatients aged ≥50 years who received ≥1 anti-VEGF injection in the past 6 months. Telephone interviews were conducted with 13 neovascular AMDpatient caregivers. RESULTS: Fifty-six physicians provided data for 221 patients with neovascular AMD. Patients accounted for 20% of the health care staff's time per week, with an average of 23 staff members. An average patient visit for neovascular AMD was 90 minutes (range: 13 minutes to >4 hours). Patients reported an average time per visit of almost 12 hours, including preappointment preparation (16 minutes), travel (66 minutes), waiting time (37 minutes), treatment time (43 minutes), and postappointment recovery (9 hours). Patients stated that caregivers took time away from work (22%) and personal activities (28%) to provide transportation to appointments. CONCLUSIONS:Neovascular AMD management imposes a substantial time burden on physicians, staff, patients, and caregivers. There may be a need for additional support and/or reimbursement for services required by patients and caregivers and provided by physicians.
Authors: Paola S Calles-Monar; María R Sanabria; Ana M Alonso-Tarancon; Rosa M Coco-Martin; Agustín Mayo-Iscar Journal: Drugs Aging Date: 2022-04-29 Impact factor: 3.923
Authors: Shrirang V Ranade; Mark R Wieland; Tammy Tam; Jennifer C Rea; Judit Horvath; Aaron R Hieb; Weitao Jia; Lori Grace; Giulio Barteselli; Jay M Stewart Journal: Drug Deliv Date: 2022-12 Impact factor: 6.819
Authors: Sean F Hackett; Jie Fu; Yoo Chun Kim; Hiroki Tsujinaka; Jikui Shen; Raquel Lima E Silva; Mahmood Khan; Zibran Hafiz; Tao Wang; Matthew Shin; Nicole M Anders; Ping He; Laura M Ensign; Justin Hanes; Peter A Campochiaro Journal: Biomaterials Date: 2020-03-04 Impact factor: 12.479
Authors: Nrupen A Bhavsar; Kate Bloom; Jonathan Nicolla; Callie Gable; Abby Goodman; Andrew Olson; Matthew Harker; Janet Bull; Donald H Taylor Journal: J Palliat Med Date: 2017-05-31 Impact factor: 2.947